TY - JOUR
T1 - Microfibrillar-associated protein 4
T2 - A potential biomarker of chronic obstructive pulmonary disease
AU - Johansson, Sofie Lock
AU - Roberts, Nassim Bazeghi
AU - Schlosser, Anders
AU - Andersen, Claus B
AU - Carlsen, Jørn
AU - Wulf-Johansson, Helle
AU - Sækmose, Susanne Gjørup
AU - Titlestad, Ingrid L
AU - Tornoe, Ida
AU - Miller, Bruce
AU - Tal-Singer, Ruth
AU - Holmskov, Uffe
AU - Vestbo, Jørgen
AU - Sorensen, Grith Lykke
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Background Microfibrillar-associated protein 4 (MFAP4) is a matricellular glycoprotein that co-localises with elastic fibres and is highly expressed in the lungs. The aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD). Methods pMFAP4 was measured by an AlphaLISA immunoassay in stable COPD (n = 69) at baseline and at follow-up until 24 months after inclusion and in acute exacerbations of COPD (AECOPD) (n = 14) at baseline and until 6 months after inclusion. Results The majority of patients (89%) were in GOLD II and III. Multiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p < 0.0001) and BODE index (p = 0.04). Negative associations were found with 6-min walking distance (p = 0.04) and bronchodilator-induced reversibility (p = 0.02). The pMFAP4 levels varied less than 25% between the baseline and a 3 month follow-up in 83% of the patients. The pMFAP4 levels appeared unaffected in the acute phase of severe AECOPD but rose to an increased stable level within one month after hospitalization. Conclusion Increased pMFAP4 was associated to the severity in COPD and has the potential to serve as a stable disease biomarker. This observation warrants confirmation in a larger longitudinal COPD population.
AB - Background Microfibrillar-associated protein 4 (MFAP4) is a matricellular glycoprotein that co-localises with elastic fibres and is highly expressed in the lungs. The aim of this study was to test the hypothesis that plasma MFAP4 (pMFAP4) reflects clinical outcomes in chronic obstructive pulmonary disease (COPD). Methods pMFAP4 was measured by an AlphaLISA immunoassay in stable COPD (n = 69) at baseline and at follow-up until 24 months after inclusion and in acute exacerbations of COPD (AECOPD) (n = 14) at baseline and until 6 months after inclusion. Results The majority of patients (89%) were in GOLD II and III. Multiple linear regressions showed positive associations between pMFAP4 and the Global initiative for Obstructive Lung Disease (GOLD) grade (p = 0.01), modified Medical Research Council score (p < 0.0001) and BODE index (p = 0.04). Negative associations were found with 6-min walking distance (p = 0.04) and bronchodilator-induced reversibility (p = 0.02). The pMFAP4 levels varied less than 25% between the baseline and a 3 month follow-up in 83% of the patients. The pMFAP4 levels appeared unaffected in the acute phase of severe AECOPD but rose to an increased stable level within one month after hospitalization. Conclusion Increased pMFAP4 was associated to the severity in COPD and has the potential to serve as a stable disease biomarker. This observation warrants confirmation in a larger longitudinal COPD population.
U2 - 10.1016/j.rmed.2014.06.003
DO - 10.1016/j.rmed.2014.06.003
M3 - Journal article
C2 - 25022422
SN - 0954-6111
VL - 108
SP - 1336
EP - 1344
JO - Respiratory Medicine
JF - Respiratory Medicine
IS - 9
ER -